Clinical predictors of N2 disease in non-small cell lung cancer

Citation
K. Takamochi et al., Clinical predictors of N2 disease in non-small cell lung cancer, CHEST, 117(6), 2000, pp. 1577-1582
Citations number
33
Categorie Soggetti
Cardiovascular & Respiratory Systems","Cardiovascular & Hematology Research
Journal title
CHEST
ISSN journal
00123692 → ACNP
Volume
117
Issue
6
Year of publication
2000
Pages
1577 - 1582
Database
ISI
SICI code
0012-3692(200006)117:6<1577:CPONDI>2.0.ZU;2-Y
Abstract
Objectives: To identify clinical or radiologic predictors of mediastinal ly mph node involvement in patients with non-small cell lung cancer, and to de fine the indications of preoperative mediastinoscopy. Methods: From August 1992 through April 1997, 387 patients with lung cancer (290 adenocarcinoma and 97 squamous cell carcinoma) underwent surgical res ection, We retrospectively measured all mediastinal lymph node sizes both i n the shortest and longest axes on contrast-enhanced CT scan to determine t he optimal size criteria. Using multivariate logistic regression analysis, we identified clinical or radiologic predictors of N2 disease. Results: We could not identify reliable size criteria for nodal involvement . We found two significant predictive factors of N2 disease on the basis of multivariable analysis: maximum tumor dimension and serum carcinoembryonic antigen (CEA) concentrations. The lymph node size did not prove to be a si gnificant factor. Among 50 patients with serum CEA concentrations < 5.0 mg/ mL and maximum turner dimension < 20 mm, pathologic N2 disease was proven o nly in three patients (6%), regardless of the lymph node size on CT scan. A mong 140 patients with serum CEA concentrations greater than or equal to 5. 0 ng/mL and maximum tumor dimension greater than or equal to 20 mm, approxi mately one third (n = 46) showed N2 disease. Conclusion: Serum CEA concentrations and maximum tumor dimension were more valuable in predicting N2 disease than the lymph node size on CT scan. Medi astinoscopy is indicated in patients with serum CEA concentrations < 5.0 ng /mL and maximum tumor dimension greater than or equal to 20 mm, and not ind icated in patients with serum CEA concentrations < 5.0 ng/mL and maximum tu mor dimension < 20 mm.